Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar

Executive Summary

Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)

You may also be interested in...



FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says

FDA's increasing requirements for clinical meaningfulness in efficacy measures make it more difficult to predict the agency's regulatory actions, former division director Ray Lipicky says

FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says

FDA's increasing requirements for clinical meaningfulness in efficacy measures make it more difficult to predict the agency's regulatory actions, former division director Ray Lipicky says

Oncologic Accelerated Approval Best Based On Pivotal Trial Interim Analysis

FDA is encouraging sponsors to use data from an interim analysis of an ongoing pivotal trial to support accelerated approval of cancer products, rather than relying on separate postmarketing studies

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS046710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel